Thyroid

Serious interaction requiring monitoring; see WARNINGS section for detailed guidance.

Thyroid hormones increase catabolism of vitamin K-dependent clotting factors, impairing compensatory increases in clotting factor synthesis. Patients stabilized on oral anticoagulants starting thyroid replacement require close monitoring and likely need anticoagulant dose reduction.

Thyroid products produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

May produce hyperglycemia and lead to loss of glycemic control.

Cholestyramine may delay or reduce the absorption of thyroid preparations.

Cholestyramine may delay or reduce the absorption of thyroid preparations.

Cholestyramine may delay or reduce absorption of thyroid preparations.

Colestipol binds levothyroxine and liothyronine in the intestine, impairing absorption. Four to five hours should elapse between administration of colestipol and thyroid hormones.

Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.

Administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.

Anti-thyroid drugs used with iodine supplementation may lead to hypothyroidism.

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

May produce hyperglycemia and lead to loss of glycemic control; close monitoring recommended.

Estrogens increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid glands on thyroid replacement may need increased thyroid doses.

Thyroid products may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Thyroid products may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Thyroid products may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.

Thyroid products tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.

Initiating thyroid replacement therapy may cause increases in insulin requirements. Patients receiving insulin should be closely monitored during thyroid replacement initiation.

Thyroid products may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and increased glucose monitoring may be required.

Estrogen-containing oral contraceptives increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid glands may need increased thyroid doses.

Anti-thyroid drugs used with iodine supplementation may lead to hypothyroidism.

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.